Thomas R Milam

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The abuse potential of drugs that stimulate dopamine release has driven the search for drugs that influence alternate neurotransmitters, and the glutaminergic pathway is a potential target for the development of new therapeutic practices [1]. Gabapentin is one such drug that modulates GABA and glutamate levels; its clinical effectiveness has been reported(More)
  • 1